Candida under the lens: species diversity and antifungal susceptibility trends
DOI:
https://doi.org/10.18203/2320-6012.ijrms20263102Keywords:
Broth microdilution method, C. albicans, Fluconazole, Non-albicans Candida, ResistanceAbstract
Background: Non-albicans Candida (NAC) species are increasingly responsible for mucosal and invasive candidiasis and often exhibit reduced susceptibility to antifungal agents. This study assessed the species distribution of clinical Candida isolates and their antifungal susceptibility profiles.
Methods: In a prospective study conducted from 2015 to 2018 at a tertiary care center in Varanasi, India, 711 Candida isolates obtained from blood, urine, aspirates, and mucosal swabs were analyzed. Species identification was performed using PCR-restriction fragment length polymorphism (PCR-RFLP); unresolved isolates were further characterized by MALDI-TOF mass spectrometry and sequencing.
Results: Antifungal susceptibility to fluconazole, voriconazole, caspofungin, and amphotericin B was determined using the CLSI broth microdilution method. NAC species accounted for 63% of isolates, with Candida tropicalis being the most prevalent. PCR-RFLP identified 92.5% of isolates, while MALDI-TOF MS and sequencing enabled identification of rare species, including C. mesorugosa, C. africana, and Pichia farinosa. Fluconazole showed high activity against C. albicans (94.3%) and C. glabrata (100%) but reduced activity against C. tropicalis (77.9%). Voriconazole demonstrated broad activity across species, and caspofungin exhibited low MICs for most isolates, although resistance was observed in 10.6% of C. glabrata. Amphotericin B remained active against most species, with elevated MICs noted in C. lusitaniae.
Conclusions: These findings underscore the importance of accurate species-level identification and routine antifungal susceptibility testing to optimize therapy for Candida infections.
References
Hani U, Shivakumar H, Vaghela R, Osmani MR, Shrivastava A. Candidiasis: a fungal infection- current challenges and progress in prevention and treatment. Infect Disord Drug Targets. 2015;15(1):42-52.
Arendrup MC, Patterson TF. Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017;216(3):S445-51.
Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014;20(6):5-10.
Karimi L, Mirhendi H, Khodadadi H, Mohammadi R. Molecular identification of uncommon clinical yeast species in Iran. Curr Med Mycol. 2015;1(2):1-6.
Pandey N, Gupta MK, Paul P, Tilak R. Necessity to identify candida species accurately with minimum inhibitory concentration determination in each case of bloodstream infections. J Infect Public Health. 2020;13(5):753-8.
Wiederhold NP. Antifungal resistance: current trends and future strategies to combat. Infect Drug Resist. 2017;10:249-59.
Mohammadi R, Mirhendi H, Rezaei-Matehkolaei A, Ghahri M, Shidfar MR, Jalalizand N, et al. Molecular identification and distribution profile of Candida species isolated from Iranian patients. Med Mycol. 2013;51(6):657-63.
Zhang YJ, Zhang S, Liu XZ, Wen HA, Wang M. A simple method of genomic DNA extraction suitable for analysis of bulk fungal strains: fungal DNA isolation by thermolysis. Lett Appl Microbiol. 2010;51(1):114-8.
Ghosh AK, Paul S, Sood P, Rudramurthy SM, Rajbanshi A, Jillwin TJ, et al. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry for the rapid identification of yeasts causing bloodstream infections. Clin Microbiol Infect. 2015;21(4):372-8.
CLSI document. M27-A3: reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. Wayne; 2008.
Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol. 2004;42(10):4419-31.
Miceli MH, Díaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis. 2011;11(2):142-51.
Lacroix C, Gicquel A, Sendid B, Meyer J, Accoceberry I, François N, et al. Evaluation of two matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) systems for the identification of Candida species. Clin Microbiol Infect. 2014;20(2):153-8.
Slechta ES, Hohmann SL, Simmon K, Hanson KE. Internal transcribed spacer region sequence analysis using SmartGene IDNS software for the identification of unusual clinical yeast isolates. Med Mycol. 2012;50(5):458-66.
Singh T, Kashyap AK, Ahluwalia G, Chinna D, Sidhu SS. Epidemiology of fungal infections in critical care setting of a tertiary care teaching hospital in North India: a prospective surveillance study. J Clin Sci Res. 2014;3(1):14-25.
Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother. 2018;73(1):i4-13.
Kaur R, Dhakad MS, Goyal R, Kumar R. Emergence of non-albicans Candida species and antifungal resistance in intensive care unit patients. Asian Pac J Trop Biomed. 2016;6(5):455-60.
Mohanraj H, Vinodhini VM, Vajravelu LK. Evaluation of epidemiological pattern of Candida species associated with candidemia from A tertiary care facility in South India. J Pure Appl Microbiol. 2024;18(3):1949-58.
Lockhart SR, Iqbal N, Cleveland AA, Farley MM, Harrison LH, Bolden CB, et al. Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two US cities from 2008 to 2011. J Clin Microbiol. 2012;50(11):3435-42.
Matsumoto E, Boyken L, Tendolkar S, McDanel J, Castanheira M, Pfaller M, et al. Candidemia surveillance in Iowa: emergence of echinocandin resistance. Diagn Microbiol Infect Dis. 2014;79(2):205-8.
Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999;12(4):501-17.
Tan TY, Hsu LY, Alejandria MM, Chaiwarith R, Chinniah T, Chayakulkeeree M, et al. Antifungal susceptibility of invasive Candida bloodstream isolates from the Asia-Pacific region. Med Mycol. 2016;54(5):471-7.
Posteraro B, Spanu T, Fiori B, De Maio F, De Carolis E, Giaquinto A, et al. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital. Antimicrob Agents Chemother. 2015;59(7):3944-55.
Deorukhkar S, Saini S. Non albicans Candida species: its isolation pattern, species distribution, virulence factors and antifungal susceptibility profile. Int J Med Sci Public Health. 2013;2(3):533.
Cuenca-Estrella M, Gomez-Lopez A, Cuesta I, Zaragoza O, Mellado E, Rodriguez-Tudela JL, et al. Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother. 2011;55(4):1794-7.
Wisplinghoff H, Ebbers J, Geurtz L, Stefanik D, Major Y, Edmond MB, et al. Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. Int J Antimicrob Agents. 2014;43(1):78-81.
Dagi HT, Findik D, Senkeles C, Arslan U. Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey. Ann Clin Microbiol Antimicrob. 2016;15(1):36.
Downloads
Published
How to Cite
Issue
Section
